Brainstorming this, nothing else, but it has been

Brainstorming this, nothing else, but it has been said that there are logistical companies that would be able to handle worldwide distribution to the major areas that would be using top drugs as we expect Brilacidin to become.

I don't see IPIX trying to become an independent supplier of Brilacidin across all indications, just for CV/flu/other pandemic type situations where we are dealing with supplying product to governments or hospital systems that know there are but an extremely few choices of product and Brilacidin is one of the major ones, if not the only one. For those indications where we decide a BP is worthwhile and necessary, I expect us to laugh in the face of BPs that expect they get such indications and 85% or more of resulting revenues when they did next to nothing to bring such indications to market and assumed no risk whatsoever in their development. IMO we should see HEFTY double digit royalty rates - won't project any more detailed than that.

If IPIX ever did decide to use such a partner as a worldwide representative or logistics system, such a firm would undoubtedly not be quite as effective as having a BP pushing the product, but when you are talking about revenue streams in the tens of billions and you think your drug should be a heavy player in such streams, that leaves a LOT of room for establishing warehouses, putting in inventory, and delivering product in a timely manner. Considering you are paying only the expenses of such logistical concerns and are receiving 100% of the resulting income instead of only getting 12% or so of total sales (as many seem to think is a good deal now when signing w/ a BP licensee/partner), then that leaves a lot to provide to such a worldwide representative. I owned a rep firm and we made 5% of sales and were damned happy with that (std rate for industrial reps for the most part), especially when those revenues had remote possibilities of being in the billions (we were ecstatic when a line had sales in the multi-millions). You would find some major firms IMO that would go below 5% as long as they got paid on ALL sales (in most cases after a certain amt of sales the supplier wanted a reduction in the 5% fee, even though they were really only hurting themselves as the effort goes where the money is).

I know this is not the standard, some think it is taboo, but then aren't we looking/talking about changing the system so that FDA doesn't take 12 yrs and $1B+ to get a drug to market? Same thing with distribution, maybe the day of the major BP is getting long in the tooth and needs to be looked at with a jaundiced eye.

Simply something to think about.

Edit: As for Kevetrin, we are at a loss now w/ no scientific/medical expert in the house so I assume we would hire someone to help finalize the pill formulation for the remaining tox studies and then once we get the pill tested and found safe and effective, we then would likely sign on w/ a BP or else if mgt decides it is going to be almost completely a complementary product, we don't use a BP partner but use the companies who are using it to complement their drug to garner the large revenue streams. Remember, Kevetrin is allowing their money maker to become an additonal 15 yr or so producer via the new patent so somewhere near 50% should be realistic (+/- 20%) IMO